<DOC>
	<DOC>NCT01507727</DOC>
	<brief_summary>This drug has been developed to treat Hyponatremia. The primary purpose of this study is to verify the efficacy and safety of seven-day repeated oral administration of tolvaptan at 15, 30, and 60 mg or placebo in patients with Non-hypovolemic Non-acute Hyponatremia secondary to Congestive Heart Failure (CHF), hepatic cirrhosis or Syndrome of Inappropriate Antidiuretic Hormone (SIADH), despite receiving standard therapy. This study is being conducted in China.</brief_summary>
	<brief_title>Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia</brief_title>
	<detailed_description />
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Inclusion Criteria (for CHF): 1. Patients with CHF who exhibit edema, jugular venous distention, hepatomegaly, or pulmonary congestion. 2. Nonhypovolemic and Nonacute hyponatremia with a serum sodium &lt; 135mEq/L before randomization. 3. Patients who have taken furosemide at 40 mg/d or more (oral dosing) without alteration of dosage for the 3 days of the observation period. 4. Patients whose body weight has been stable (±1.0 kg) for 2 days prior to commencement of study drug administration. 5. Age:18～80 (when informed consent is obtained)，male or female. 6. Inpatient subjects. 7. Informed consent. Inclusion Criteria (for hepatic cirrhosis): 1. Patients with hepatic edema. 2. Nonhypovolemic and non acute hyponatremia with a serum sodium &lt; 135mEq/L before randomization. 3. Age:18～65 (when informed consent is obtained)，male or female. 4. Inpatient subjects. 5. Informed consent. Inclusion Criteria (for SIADH and others): 1. Patients with SIADH arising from a variety of etiologies. 2. Nonhypovolemic and non acute hyponatremia with a serum sodium &lt; 135mEq/L before randomization. 3. Age:18～80 (when informed consent is obtained)，male or female. 4. Inpatient subjects. 5. Informed consent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>hyponatremia</keyword>
	<keyword>Non-hypovolemic and Non-acute hyponatremia</keyword>
	<keyword>Tolvaptan</keyword>
</DOC>